Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon
04:30pm, Thursday, 03'rd Aug 2023
Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration.
Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline
02:15pm, Thursday, 03'rd Aug 2023
Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.
Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential
12:58pm, Thursday, 03'rd Aug 2023
Regeneron Pharmaceuticals Inc ( REGN , Financial), a leading player in the biotechnology industry, is currently trading at $780.98 with a market capitalization of $85.68 billion. The company's stock p
Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat
10:40am, Thursday, 03'rd Aug 2023
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations.
Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue
08:11am, Thursday, 03'rd Aug 2023
Shares of Regeneron Pharmaceuticals Inc. REGN, -0.94% climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported second-quarter profit and revenue that r
Regeneron Pharma beats profit estimates on Dupixent demand
06:37am, Thursday, 03'rd Aug 2023
Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
02:59pm, Tuesday, 01'st Aug 2023
The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
02:00pm, Friday, 28'th Jul 2023
Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
01:23pm, Wednesday, 26'th Jul 2023
The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to kn
3 Pharma Stocks That AI is Loving in July
09:24pm, Thursday, 13'th Jul 2023
When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, su
3 Biotech Stocks to Buy for Long-Term Gains
07:01am, Thursday, 13'th Jul 2023
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
08:53pm, Tuesday, 11'th Jul 2023
Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of succes
Is Regeneron Stock a Buy After a Regulatory Blow?
07:00am, Friday, 07'th Jul 2023
Regeneron recently failed to earn approval for an important candidate. The biotech company should get over this regulatory hump eventually.
Is Regeneron's Stock in Trouble After This FDA Rejection?
07:50am, Thursday, 06'th Jul 2023
The Food and Drug Administration didn't approve Regeneron's higher-dose version of Eylea. Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or effi
The 3 Best Biotech Stocks to Buy In July
01:05pm, Wednesday, 05'th Jul 2023
Although it's been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at
